Literature DB >> 9877220

NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in mice.

H S Kim1, I S Park, W K Park.   

Abstract

The purpose of this study was to characterize behavioral interactions between glutamatergic and serotonergic 5-HT2 receptors. Both competitive (AP-5 [D-2-amino-5-phosphovalerate] and D-CPP [3-(2carboxypiperazine-4yl)-propylphosphonate]) and noncompetitive (MK-801 [dizocilpine], ketamine, dextrorphan and dextromethorphan) N-methyl-D-aspartate (NMDA) receptor antagonists markedly enhanced a selective serotonergic behavior, the head twitch response (HTR), in mice. In contrast, NMDA itself inhibited 5-hydroxytryptamine (5-HT)-induced HTR in mice. These results suggest that glutamatergic neurotransmission may modulate serotonergic function at the 5-HT2 receptor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9877220     DOI: 10.1016/s0024-3205(98)00519-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  15 in total

1.  Assessment of the effect of dextromethorphan and ketamine on the acute nociceptive threshold and wind-up of the second pain response in healthy male volunteers.

Authors:  A M Hughes; J Rhodes; G Fisher; M Sellers; J W Growcott
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

Review 2.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.

Authors:  Clint E Canal; Drake Morgan
Journal:  Drug Test Anal       Date:  2012-04-19       Impact factor: 3.345

Review 3.  Serotonergic system, cognition, and BPSD in Alzheimer's disease.

Authors:  Saikat Chakraborty; Jack C Lennon; Sridhar A Malkaram; Yan Zeng; Daniel W Fisher; Hongxin Dong
Journal:  Neurosci Lett       Date:  2019-04-01       Impact factor: 3.046

4.  Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).

Authors:  Simon D Brandt; Pierce V Kavanagh; Brendan Twamley; Folker Westphal; Simon P Elliott; Jason Wallach; Alexander Stratford; Landon M Klein; John D McCorvy; David E Nichols; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2017-07-27       Impact factor: 3.345

5.  Predicting targets of compounds against neurological diseases using cheminformatic methodology.

Authors:  Katarina Nikolic; Lazaros Mavridis; Oscar M Bautista-Aguilera; José Marco-Contelles; Holger Stark; Maria do Carmo Carreiras; Ilaria Rossi; Paola Massarelli; Danica Agbaba; Rona R Ramsay; John B O Mitchell
Journal:  J Comput Aided Mol Des       Date:  2014-11-26       Impact factor: 3.686

6.  Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy.

Authors:  Ouissame Mnie-Filali; Céline Faure; Laura Lambás-Señas; Mostafa El Mansari; Hassina Belblidia; Elise Gondard; Adeline Etiévant; Hélène Scarna; Anne Didier; Anne Berod; Pierre Blier; Nasser Haddjeri
Journal:  Neuropsychopharmacology       Date:  2011-02-16       Impact factor: 7.853

7.  Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli.

Authors:  J C Winter; J R Eckler; R A Rabin
Journal:  Psychopharmacology (Berl)       Date:  2003-11-04       Impact factor: 4.530

8.  Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered.

Authors:  I Gaisler-Salomon; L Diamant; C Rubin; I Weiner
Journal:  Psychopharmacology (Berl)       Date:  2007-10-11       Impact factor: 4.530

9.  D-serine deficiency attenuates the behavioral and cellular effects induced by the hallucinogenic 5-HT(2A) receptor agonist DOI.

Authors:  Martin A Santini; Darrick T Balu; Matthew D Puhl; Tiffany E Hill-Smith; Alexandra R Berg; Irwin Lucki; Jens D Mikkelsen; Joseph T Coyle
Journal:  Behav Brain Res       Date:  2013-11-20       Impact factor: 3.332

Review 10.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.